EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends in incidence, prevalence, and survival of primary liver cancer in the United Kingdom (2000–2021)

Berta Cuyàs, Edilmar Alvarado-Tapias, Eng Hooi Tan iD, Asieh Golozar, Talita Duarte-Salles iD, Antonella Delmestri, Josepmaria Argemi, Wai Yi Man, Edward Burn iD, Carlos Guarner-Argente, Daniel Prieto Alhambra iD, Danielle Newby

European Journal of Public Health · 14.03.2026 · 36 (2)

DOI: 10.1093/eurpub/ckaf153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Public Health, online erschienen am 10.11.2025. Verfasst von Berta Cuyàs und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 (IMI2) Joint Undertaking, European Union's Horizon 2020 Research and Innovation Programme and European Federation of Pharmaceutical Industries and Associations (EFPIA), Oxford NIHR Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary liver cancer (PLC) remains a global health challenge. Understanding trends in the disease burden and survival is crucial to inform decisions regarding screening, prevention, and treatment. Population-based cohort study using UK primary care data from the Clinical Practice Research Datalink (CPRD) GOLD (2000–2021), replicated in CPRD Aurum. Crude and age-standardized incidence rates (IRs), crude period prevalence (PP), and survival at 1, 5, and 10 years were calculated, and stratified by age, sex, and diagnosis year. The crude IR of PLC was 4.56 (95% CI 4.42–4.70) per 100 000 person-years between 2000 and 2021, with an increase over time across age and sex strata. Sex-specific IR for males was higher than females, 6.60 (95% CI 6.36–6.85) vs. 2.58 (95% CI 2.44–2.74) per 100 000 person-years. Age-standardized IR showed identical trends. Crude PP showed a seven-fold increase over the study period, with PP 0.02% (95% CI 0.019%–0.022%) in 2021, and a 2.8-fold higher PP in males. Survival at 1, 5, and 10 years after diagnosis was 41.7%, 13.2%, and 7.1%, respectively, for both sexes. One-year survival increased only in men, from 33.2% in 2005–2009 to 49.3% in 2015–2019. Over the past two decades, there has been a substantial increase in the number of patients diagnosed with PLC. Despite a slight improvement in median and one-year survival in men, prognosis remains poor. To improve the survival of PLC patients, it is necessary to understand the epidemiological changes and address preventable risk factors associated with liver disease and promote early detection and access to care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsHumansMaleFemaleUnited KingdomIncidenceMiddle AgedAgedPrevalenceAdultCohort StudiesAged, 80 and overYoung AdultAdolescent

Autor:innen und Institutionen

  • Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Medicine Department, Autonomous University of Barcelona (UAB), Barcelona, Spain.
  • Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
  • Nemesis Health, New York, NY, United States.
  • OHDSI Center at the Roux Institute, Northeastern University, Boston, MA, United States.

ORCID-Profile: Eng Hooi Tan, Talita Duarte-Salles, Edward Burn, Daniel Prieto Alhambra

Förderung

  • Innovative Medicines Initiative 2 (IMI2) Joint Undertaking
  • European Union's Horizon 2020 Research and Innovation Programme and European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Oxford NIHR Biomedical Research Centre
  • ISCII
  • ISCIII-Fondos Feder
  • European Union’s Horizon 2020 Research and Innovation Programme and European Federation of Pharmaceutical Industries and Associations

Zitieren

APA

Cuyàs, B., Alvarado-Tapias, E., Tan, E. H., Golozar, A., Duarte-Salles, T., Delmestri, A., Argemi, J., Man, W. Y., Burn, E., Guarner-Argente, C., Prieto Alhambra, D., & Newby, D. (2026). Trends in incidence, prevalence, and survival of primary liver cancer in the United Kingdom (2000–2021). European Journal of Public Health, 36(2). https://doi.org/10.1093/eurpub/ckaf153

Vancouver

Cuyàs B, Alvarado-Tapias E, Tan EH, Golozar A, Duarte-Salles T, Delmestri A, et al. Trends in incidence, prevalence, and survival of primary liver cancer in the United Kingdom (2000–2021). European Journal of Public Health. 2026;36(2). doi:10.1093/eurpub/ckaf153

BibTeX
@article{Cuys2026,
  author = {Cuyàs, Berta and Alvarado-Tapias, Edilmar and Tan, Eng Hooi and Golozar, Asieh and Duarte-Salles, Talita and Delmestri, Antonella and Argemi, Josepmaria and Man, Wai Yi and Burn, Edward and Guarner-Argente, Carlos and Prieto Alhambra, Daniel and Newby, Danielle},
  title = {Trends in incidence, prevalence, and survival of primary liver cancer in the United Kingdom (2000–2021)},
  journal = {European Journal of Public Health},
  year = {2026},
  volume = {36},
  number = {2},
  doi = {10.1093/eurpub/ckaf153}
}
Kostenlos starten →